RxDoctor Payments Data

Ambar Kulshreshtha, MD

Family Medicine · Atlanta, GANPI 1326313750

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,308 of the $14,084 with a category attached, or 87.4%. 5 manufacturers reported payments, led by Lilly USA, LLC at 59.7% of the total. Among family medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,084in general payments, 2019–2025

Across 14 payments — averaging $1006.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$8K
  • Novo Nordisk$5K
  • Amgen$164
  • Gilead$106
  • Corium, LLC$91
$26,466in research payments, 2019–2025

Across 1 payment — averaging $26,466 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cleerly, Inc.$26K

What the payments were for

  • Consulting fees$12,30887%
  • Travel & lodging$1,1198%
  • Food & beverage$6585%

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$8,407
Novo Nordisk4$5,317
Amgen2$164
Gilead1$106
Corium, LLC1$91

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,084 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$20,597
Medicare patients
107
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$36,779
OzempicSemaglutide17$19,025
JanuviaSitagliptin Phosphate16$16,206
Memantine Hcl299$11,707
Aripiprazole70$10,292
Rivastigmine22$6,723
Quetiapine Fumarate327$5,579
Fluoxetine Hcl76$4,289
Duloxetine Hcl118$4,270
Donepezil Hcl273$4,228
Atorvastatin Calcium344$3,654
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,488
Olanzapine OdtOlanzapine15$3,399
Escitalopram Oxalate189$3,157
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$2,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$5,317$19,02517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →